Abstract
A preliminary analysis is presented of a clinical trial to determine whether adjuvant immunotherapy or chemotherapy can prolong the disease-free interval and survival of patients with poor prognosis Stage I malignant melanoma or Stage II melanoma. Postsurgical patients were randomized to receive either no further treatment, bacille Calmette Guerin (BCG); BCG plus neuraminidase-treated, allogeneic, tissue-cultured melanoma cells; or methyl-CCNU. No statistically significant improvement in disease-free interval or overall survival has been noted.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
